Total Funding
15
Total FundingSeries A raised
Growth Score
pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
110192
Novosteo, test the efficacy of a new drug to help reduce complications from a broken bone due to a fall.
- Dan Hasler: CEO
Philip Low: Co-founder & DirectorPast Role: Endocyte, Co-Founder, Chief Science Officer & Board Member
About the Company
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a
proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.
